Enrico Cavallo

Dr. Enrico Cavallo


Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 January 2024 in Diagnostics
Verified
Journal Article
Open access
PDF file
SMStefano Marletta
Stefano Marletta
AGAlexandra Giorlandino
Alexandra Giorlandino
ECEnrico Cavallo
Enrico Cavallo
MVMichele Dello Spedale Venti
Michele Dello Spedale Venti
GLGiorgia Leone
Giorgia Leone
ARAntonio Rizzo
Antonio Rizzo
Background: Breast cancer (BC) is a heterogeneous disease made up of clones with different metastatic potential. Intratumoral heterogeneity may cause metastases to show divergent biomarker expression, potentially affecting chemotherapy response. Methods: We investigated the immunohistochemical (IHC) and FISH profile of estrogen receptors (ER), progesterone (PR) receptors, Ki67, and HER2 in a series of BC-matched primary tumors (PTs) and axillary lymph node (ALN) metastases in pre-operative core needle biopsies (CNBs). Phenotypical findings were correlated to morphological features and their clinical implications. Results: Divergent expression between PTs and ALNs was found in 10% of the tumors, often involving multiple biomarkers (12/31, 39%). Most (52%) displayed significant differences in ER and PR staining. HER2 divergences were observed in almost three-quarters of the cases (23/31, 74%), with five (16%) switching from negativity to overexpression/amplification in ALNs. Roughly 90% of disparities reflected significant morphological differences between PTs and ALN metastases. Less than half of the discrepancies (12/31, 39%) modified pre/post-operative treatment options. Conclusions: We observed relevant discrepancies in biomarker expression between PTs and metastatic ALNs in a noteworthy proportion (10%) of preoperative BC CNBs, which were often able to influence therapies. Hence, our data suggest routine preoperative assessment of biomarkers in both PTs and ALNs in cases showing significant morphological differences.

22 August 2026 in Diagnostics
Verified
Journal Article
Open access
PDF file
SMStefano Marletta
Stefano Marletta
ECEnrico Cavallo
Enrico Cavallo
MVMichele Dello Spedale Venti
Michele Dello Spedale Venti
GBGiacomo Bonanno
Giacomo Bonanno
FRFabio Romeo
Fabio Romeo
MNMARIANGELA NOVELLO
MARIANGELA NOVELLO
Background and Clinical Significance: Primary pancreatic extramedullary plasmacytomas (EMP) are extremely uncommon, representing less than 0.1% of all pancreatic masses and being far more uncommon than secondary involvement by an underlying multiple myeloma. Case presentation: A 69-year-old male was found with a solitary pancreatic mass. Endoscopic ultrasound (EUS)-guided fine-needle biopsy (FNB) revealed a monoclonal plasmacytic proliferation with molecularly confirmed KRAS (A146V) and BRAF (G469V) mutations. Multidisciplinary assessment ruled out a secondary localization, thus leading to the ultimate diagnosis of primary pancreatic EMP. Conclusions: Reaching a definitive diagnosis of primary pancreatic EMP requires a negative bone marrow biopsy and histological confirmation of the plasma cell nature of the pancreatic process. As for the latter, EUS-FNB may be a pivotal technique to avoid upfront surgical procedures.